InnoCare and Keymed Announce First Dosing of ICP-B05 Clinical Study
China-based firms InnoCare Pharma (HKG: 9969, SHA: 688428) and Keymed Biosciences (HKG: 2162) have jointly...
SHA: 688428
InnoCare Pharma Receives Hong Kong Approval for Tafasitamab in DLBCL
China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the...
InnoCare Pharma’s Orelabrutinib Placed on Partial Clinical Hold by FDA
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that the US FDA has placed...
InnoCare Receives CDE Approval for Phase II Trial of Orelabrutinib Combination
China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving approval from China’s Center...
InnoCare Pharma’s Hibruka Receives HSA Approval for Mantle Cell Lymphoma in Singapore
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the Health...